AngioDynamics/$ANGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AngioDynamics
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Ticker
$ANGO
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
748
ISIN
US03475V1017
Website
AngioDynamics Metrics
BasicAdvanced
$415M
-
-$1.02
0.52
-
Price and volume
Market cap
$415M
Beta
0.52
52-week high
$13.50
52-week low
$5.47
Average daily volume
599K
Financial strength
Current ratio
2.209
Quick ratio
1.202
Long term debt to equity
4.557
Total debt to equity
5.755
Profitability
EBITDA (TTM)
-7.61
Gross margin (TTM)
54.36%
Net profit margin (TTM)
-14.61%
Operating margin (TTM)
-11.29%
Effective tax rate (TTM)
1.60%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-6.55%
Return on equity (TTM)
-20.46%
Valuation
Price to revenue (TTM)
1.47
Price to book
2.25
Price to tangible book (TTM)
3.65
Price to free cash flow (TTM)
-14.774
Free cash flow yield (TTM)
-6.77%
Free cash flow per share (TTM)
-69.24%
Growth
Revenue change (TTM)
-12.56%
Earnings per share change (TTM)
-78.87%
3-year revenue growth (CAGR)
-2.54%
10-year revenue growth (CAGR)
-2.26%
3-year earnings per share growth (CAGR)
-0.21%
10-year earnings per share growth (CAGR)
25.68%
What the Analysts think about AngioDynamics
Analyst ratings (Buy, Hold, Sell) for AngioDynamics stock.
Bulls say / Bears say
AngioDynamics reported a third-quarter fiscal 2025 adjusted EPS of $0.03, surpassing the consensus estimate of a $0.13 loss, indicating improved financial performance. (benzinga.com)
The company's Med Tech segment achieved a 22.2% increase in net sales, driven by strong growth across all product lines, including a 161.4% rise in AlphaVac sales, showcasing robust demand for its innovative products. (benzinga.com)
AngioDynamics received European CE Mark approval for its AlphaVac F1885 System, expanding its market reach and potential revenue streams in the European market. (businesswire.com)
AngioDynamics revised its fiscal 2024 net sales guidance downward to $270 million-$275 million from the earlier outlook of $320 million-$325 million, reflecting challenges in meeting previous revenue expectations. (finance.yahoo.com)
The company reported a 4.2% decline in revenue to $72 million for the quarter ended February 28, 2025, compared to the same period a year ago, indicating potential difficulties in sustaining growth. (tradingview.com)
AngioDynamics announced a restructuring plan involving facility closures and employee terminations, with estimated costs ranging from $38.5 million to $43.25 million, which may impact short-term profitability. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AngioDynamics Financial Performance
Revenues and expenses
AngioDynamics Earnings Performance
Company profitability
AngioDynamics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AngioDynamics stock?
AngioDynamics (ANGO) has a market cap of $415M as of June 20, 2025.
What is the P/E ratio for AngioDynamics stock?
The price to earnings (P/E) ratio for AngioDynamics (ANGO) stock is 0 as of June 20, 2025.
Does AngioDynamics stock pay dividends?
No, AngioDynamics (ANGO) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next AngioDynamics dividend payment date?
AngioDynamics (ANGO) stock does not pay dividends to its shareholders.
What is the beta indicator for AngioDynamics?
AngioDynamics (ANGO) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.